These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 29336928)
1. Tackling the recurrence of Clostridium difficile infection. Petrosillo N Med Mal Infect; 2018 Feb; 48(1):18-22. PubMed ID: 29336928 [TBL] [Abstract][Full Text] [Related]
2. Exploring ways to improve CDI outcomes. Galpérine T; Guery B; Med Mal Infect; 2018 Feb; 48(1):10-17. PubMed ID: 29336930 [TBL] [Abstract][Full Text] [Related]
3. Best strategies in recurrent or persistent Clostridium difficile infection. Cocanour CS Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157 [TBL] [Abstract][Full Text] [Related]
4. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset. Kimura T; Snijder R; Sugitani T J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950 [TBL] [Abstract][Full Text] [Related]
5. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin. Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088 [TBL] [Abstract][Full Text] [Related]
7. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389 [TBL] [Abstract][Full Text] [Related]
8. The host immune response to Clostridium difficile. Kelly CP; Kyne L J Med Microbiol; 2011 Aug; 60(Pt 8):1070-1079. PubMed ID: 21415200 [TBL] [Abstract][Full Text] [Related]
9. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686 [TBL] [Abstract][Full Text] [Related]
10. Recurrent Song JH; Kim YS Gut Liver; 2019 Jan; 13(1):16-24. PubMed ID: 30400734 [TBL] [Abstract][Full Text] [Related]
12. The prospect for vaccines to prevent Clostridium difficile infection. Ghose C; Kelly CP Infect Dis Clin North Am; 2015 Mar; 29(1):145-62. PubMed ID: 25677708 [TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of Clostridium difficile infection. Korman TM Semin Respir Crit Care Med; 2015 Feb; 36(1):31-43. PubMed ID: 25643269 [TBL] [Abstract][Full Text] [Related]
14. Existing and investigational therapies for the treatment of Clostridium difficile infection: A focus on narrow spectrum, microbiota-sparing agents. Maxwell-Scott HG; Goldenberg SD Med Mal Infect; 2018 Feb; 48(1):1-9. PubMed ID: 29169816 [TBL] [Abstract][Full Text] [Related]
18. Characterization of Chicken IgY Specific to Pizarro-Guajardo M; Díaz-González F; Álvarez-Lobos M; Paredes-Sabja D Front Cell Infect Microbiol; 2017; 7():365. PubMed ID: 28856119 [No Abstract] [Full Text] [Related]